Cel Sci Corporation (CVM)

[meirluc]

If 784 patients is the minimum requirement per the protocol and if 40% of those 784 are low risk patients who did not receive chemotherapy, that low risk group suffered a significantly higher death rate than the high risk patients, all of whom received chemo.

Given that the 5 year survival in the non chemo treated, low risk SOC group was 48.7% and for the non chemo treated group receiving multikine it was 62.8%, the percentage of death was 51.3% in the low risk SOC group and 37.2% in the low risk Multikine treated group. The average percent of death in that combined low risk group that did not receive chemo was therefore 44.1%.

If about 40% of the 784 patients belonged in the low risk group, we had about 314 patients in that low risk group of whom 44.1% or 138 evented.

Since we had a total of 298 events of which 138 were accounted for, the remaining 160 events had to originate from the 470 patients (784-314=470) who were at high risk and received chemotherapy. That large high risk group did surprisingly slightly better than the low risk Multikine treated group and much better than the low risk group treated only with RT because whether they received Multikine or not, that chemo treated group only had a 34% event rate over a 5 year trial period.(160X100%/470=34%).

GO FIGURE.